Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2016 May 6;6(5):e417. doi: 10.1038/bcj.2016.26

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Significantly different immune cell populations in cHL. Optimized concentrations of fluorochrome-antibody conjugates were applied on cell suspensions of cHL tissue and analyzed by flow cytometry. (a–f) Significant differences in immune cell populations between RLN and EBV+ and EBV− cHL. Percentages of (a) GITR+CD25+ in CD4+ cells; (b) FoxP3+CD25+ in CD4+ cells; (c) CD16+ in CD56+ cells; (d) CD69+ in CD8+ cells; (e) Granzyme B+ in CD8+ cells; (f) TIA-1+ in CD8+ cells. An overview of all subsets tested and of all results has been given in Supplementary Tables S1–3. Lines indicate the median percentage of each group. Kruskal–Wallis test was used to test for differences in all three groups and a P-value of 0.0125 (to correct for multiple testing) was considered to be significant. Mann–Whitney U test was used as a post hoc test to identify significant differences in groups. (*P<0.05; **P<0.01). (g–i) Cell populations with significant differences between CD26− and CD26+ T cells in cHL overall and EBV-stratified subgroups. (g) Percentages of CD69+ in CD4+ cells in cHL; (h) FoxP3+ in CD4+ cells in cHL; (i) CD25+ in CD8+ cells in cHL. Lines indicate the median percentage of each group. Wilcoxon-matched-pairs signed-rank test was used to compare the two groups.